David A. Siegel Applied Therapeutics Inc. Transaction History

Two Sigma Advisers, LP

$42.8 Billion
Q1 2025

A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Applied Therapeutics Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 658,400 shares of APLT stock, worth $250,192. This represents 0.0% of its overall portfolio holdings.

Number of Shares

658,400

Holding current value

$250,192

% of portfolio

0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	BUY	$0.46 - $0.94 $302,864 - $618,896	658,400 New	658,400 $322,000
Q4 2023 Feb 14, 2024	BUY	$1.84 - $3.35 $65,136 - $118,590	35,400 Added 226.92%	51,000 $170,000
Q3 2023 Nov 14, 2023	SELL	$1.26 - $2.77 $114,749 - $252,266	-91,071 Reduced 85.38%	15,600 $38,000
Q2 2023 Aug 14, 2023	SELL	$0.77 - $1.8 $33,199 - $77,608	-43,116 Reduced 28.78%	106,671 $136,000
Q1 2023 May 15, 2023	SELL	$0.75 - $1.21 $75,084 - $121,136	-100,113 Reduced 40.06%	149,787 $121,000
Q4 2022 Feb 14, 2023	BUY	$0.54 - $1.12 $378 - $784	700 Added 0.28%	249,900 $189,000
Q3 2022 Nov 14, 2022	BUY	$0.86 - $1.55 $117,648 - $212,040	136,800 Added 121.71%	249,200 $232,000
Q2 2022 Aug 15, 2022	BUY	$0.76 - $2.64 $5,548 - $19,272	7,300 Added 6.95%	112,400 $107,000
Q1 2022 May 16, 2022	BUY	$1.48 - $6.22 $136,456 - $573,484	92,200 Added 714.73%	105,100 $222,000
Q4 2021 Feb 14, 2022	BUY	$8.77 - $18.29 $21,925 - $45,725	2,500 Added 24.04%	12,900 $115,000
Q3 2021 Nov 15, 2021	BUY	$13.54 - $22.06 $140,816 - $229,424	10,400 New	10,400 $173,000

Others Institutions Holding APLT

# of Institutions

Shares Held

103M

Call Options Held

176K

Put Options Held

165K

View Full List

About Applied Therapeutics Inc.

Ticker APLT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,020,700
Market Cap $18.2M
Description
Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-007 that has completed phase 1/2 for the treatment of galactosemia in healthy volunteers and adults, as well as is in pediatric clinical study...

More about APLT

Track David A. Siegel's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Account